Globally, about 12% of NSCLC cases carry epidermal growth factor receptor (EGFR) mutations [6], with exon 19 deletions (Ex19del) and exon 21 L858R point mutations (L858R) representing 85% to 90% of all EGFR mutations in NSCLC [7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.